Skip to main content
Search

Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)

Published on October 31, 2023   23 min

Other Talks in the Series: Drug Delivery

Please wait while the transcript is being prepared...
0:00
Hello, My name is Ana Catarina Silva and I'm an associate professor at University Fernando Pessoa and a researcher at UCIBIO Faculty of Pharmacy University of Porto, Portugal. Today I will talk about the two types of lipid nanoparticles, namely solid lipid nanoparticles or SLN, and nanostructured lipid carriers or NLC.
0:27
I will start my presentation with an overview of nanosystems followed by a detailed description of SLN and NLC. Finally, I will present some research results with this type of lipid nanoparticles and end with some conclusions.
0:47
Formulation limitations in conventional pharmaceutical dosage forms are related to several factors such as synthesis of new lipophilic drug molecules belonging to BCS classes II and IV, the development of therapeutic proteins that can be degraded by the body environment, and the development of nucleic acid based therapies which shows limitations related to their molecular characteristics. All these factors give rise to bioavailability problems.
1:23
Among the strategies that have been used to improve drug bioavailability, the most explored are the drug delivery systems, in particular the nanosystems. As it can be seen in this scale, they are nanosized colloidal carriers which are 100 to 10000 smaller than human cells.
Show
Hide

Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)

Embed in course/own notes